Forte Biosciences Inc. (FBRX)
8.89
-0.21 (-2.31%)
At close: Mar 03, 2025, 11:58 AM
No 1D chart data available
| Bid | 8.74 |
| Market Cap | 56.84M |
| Revenue (ttm) | 20.76K |
| Net Income (ttm) | -118.32M |
| EPS (ttm) | -16.38 |
| PE Ratio (ttm) | -0.54 |
| Forward PE | -4.19 |
| Analyst | Buy |
| Ask | 8.89 |
| Volume | 2,745 |
| Avg. Volume (20D) | 55,112 |
| Open | 8.98 |
| Previous Close | 9.10 |
| Day's Range | 8.89 - 9.22 |
| 52-Week Range | 4.11 - 28.68 |
| Beta | 2.79 |
About FBRX
Forte Biosciences, Inc. operates as a clinical-stage biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as vitiligo and alopecia areata. The company is headquartered in Dallas, Texas....
Industry Biotechnology
Sector Healthcare
IPO Date Apr 13, 2017
Employees 11
Stock Exchange NASDAQ
Ticker Symbol FBRX
Website https://www.fortebiorx.com
Analyst Forecast
According to 4 analyst ratings, the average rating for FBRX stock is "Buy." The 12-month stock price forecast is $68.75, which is an increase of 673.34% from the latest price.
Buy 100.00%
Hold 0.00%
Sell 0.00%
2 months ago
-18.1%
Forte Biosciences shares are trading lower after t...
Unlock content with
Pro Subscription
6 months ago
-20.51%
Forte Biosciences shares are trading lower after the company reported worse-than-expected Q2 EPS results.
